Description
Pepstatin (Pepstatin A) is a specific, orally active aspartic protease inhibitor produced by actinomycetes, with IC50s of 4.5 nM, 6.2 nM, 150 nM, 290 nM, 520 nM and 260 nM for hemoglobin-pepsin, hemoglobin-proctase, casein-pepsin, casein-proctase, casein-acid protease and hemoglobin-acid protease, respectively. Pepstatin also inhibits HIV protease[1][2].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–COVID-19-anti-virus–C34H63N5O9—Adv Sci (Weinh). 2022 Oct 10;e2203831.|Adv Sci (Weinh). 2023 Oct;10(28):e2302130.|Arch Biochem Biophys. 2023 May 22, 109646.|Biochem Bioph Res Co. 2020 Sep 10;530(1):292-300.|bioRxiv. 2023 Nov 5.|Cancer Lett. 2022 Mar 9;215629.|Carbohydr Polym. 2023 Jul 17, 121208.|Cell Death Dis. 2022 Dec 16;13(12):1048.|Cell Rep. 2021 Nov 2;37(5):109931.|Environ Sci Technol. 2017 Dec 5;51(23):13938-13948.|Eur J Pharmacol. 2022 Feb 11;920:174823.|FASEB J. 2022 Jan;36(1):e22121.|Int J Oncol. 2019 Jul;55(1):331-339.|J Virol. 2021 Sep 22;JVI0153721.|J Virol. 2023 Oct 17:e0107523.|Mol Med Rep. 2019 Jan;19(1):41-50.|Pharmaceuticals. 2022, 15(12), 1509|Pharmacol Res. 2021 Dec 1;175:105985.|PLoS Pathog. 2024 Feb 14;20(2):e1011981.|Redox Biol. 2024 Apr:70:103064.|Sci Adv. 2022 Nov 11;8(45):eabn6579.|SSRN. 2023 Apr 10.|Toxicol Appl Pharmacol. 2018 Oct 1;356:159-171. |ACS Nano. 2024 Jan 10.|Int J Antimicrob Agents. 2019 Dec;54(6):814-819.|Biol Pharm Bull. 2022 Feb 3.-[1]Umezawa H, et al. Pepstatin, a new pepsin inhibitor produced by Actinomycetes. J Antibiot (Tokyo). 1970 May;23(5):259-62.|[2]Seelmeier S, et al. Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A. Proc Natl Acad Sci U S A. 1988 Sep;85(18):6612-6.–26305-03-3–685.89–98.59–CC(C[C@H](NC([C@@H](NC([C@@H](NC(CC(C)C)=O)C(C)C)=O)C(C)C)=O)[C@@H](O)CC(N[C@@H](C)C(N[C@@H](CC(C)C)[C@@H](O)CC(O)=O)=O)=O)C–Infection; Inflammation/Immunology–DMSO : 31.25 mg/mL (ultrasonic)–Autophagy;HIV Protease—-Anti-infection;Autophagy;Metabolic Enzyme/Protease–Peptides
